Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.

Journal of neuro-AIDS Pub Date : 1996-01-01 DOI:10.1300/j128v01n04_08

T Counihan, N Venna, D Craven, T D Sabin

{"title":"Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.","authors":"T Counihan, N Venna, D Craven, T D Sabin","doi":"10.1300/j128v01n04_08","DOIUrl":null,"url":null,"abstract":"Objective: To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).Design: Open label, uncontrolled study.Setting: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.Patients: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.Intervention: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.Results: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.Conclusions: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.","PeriodicalId":73854,"journal":{"name":"Journal of neuro-AIDS","volume":"1 4","pages":"79-88"},"PeriodicalIF":0.0000,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1300/j128v01n04_08","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuro-AIDS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1300/j128v01n04_08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

Objective: To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).

Design: Open label, uncontrolled study.

Setting: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.

Patients: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.

Intervention: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.

Results: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.

Conclusions: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.

查看原文本刊更多论文

α干扰素在艾滋病相关进行性多灶性脑白质病中的作用。

目的:探讨重组干扰素α治疗获得性免疫缺陷综合征(AIDS)伴进行性多灶性白质脑病的疗效。设计:开放标签，非对照研究。地点:马萨诸塞州波士顿市医院神经内科和临床艾滋病项目。患者:连续4例经病理证实为进行性多灶性脑白质病的艾滋病患者。干预:每位患者接受α -干扰素治疗，持续4-12周，每日5-10万单位，皮下给药。此外，四人中有两人在同一时期口服阿昔洛韦2400毫克/天。结果:所有患者均无临床反应;平均生存期为14周。没有发现治疗的不良反应。结论:尽管有轶事证据表明α干扰素对非艾滋病患者进行性多灶性脑白质病变有效，但这些患者的经验表明，该药物对艾滋病相关PML没有益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuro-AIDS

自引率

0.00%

发文量